Determination of common genetic variants in cytidine deaminase (CDA) gene in Indian ethnic population

被引:7
作者
Iyer, Sandhya N. [1 ]
Ankala, Arunkanth [2 ]
Singhal, Rekha S. [1 ]
Hegde, Madhuri R. [2 ]
机构
[1] Inst Chem Technol, Food Engn & Technol Dept, Bombay 400019, Maharashtra, India
[2] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA
关键词
Pharmacogenetics; Cytidine deaminase; Sequencing; Gemcitabine; LUNG-CANCER PATIENTS; SINGLE-NUCLEOTIDE POLYMORPHISMS; ACUTE MYELOID-LEUKEMIA; PATIENTS IMPACT; GEMCITABINE; PHARMACOKINETICS; PHARMACOGENETICS; TOXICITY; CAPECITABINE; CHEMOTHERAPY;
D O I
10.1016/j.gene.2013.04.015
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cytidine deaminase (CDA) is the major enzyme involved in metabolism of gemcitabine, a pyrimidine analog widely used for chemotherapy of solid tumors. While only low amounts of administered gemcitabine undergo intracellular phosphorylation into active forms and involve in antineoplastic activities, majority of it is rapidly inactivated by CDA and excreted to avoid drug toxicity. Knowledge of the genetic polymorphisms mildly effecting cellular activity of the enzyme CDA is therefore crucial to understanding drug-induced toxicities associated with gemcitabine. Functional significance and allele frequencies for common SNPs including 79A>C (*2) and 208G>A (*3) have been reported in various ethnic populations including Caucasian, African, Korean and Japanese. However, such studies have not been reported in any Indian sub-population. In the present study, conventional polymerase chain reaction (PCR) based amplification using gene specific primers and Sanger sequencing were performed to identify CDA variants in 50 healthy individuals from Indian sub-population. Established common variant 79A>C known to reduce CDA activity was observed at a frequency of 0.14 in the study cohort. In addition to other known variants, one novel variant, c.325-209T>C was detected at a frequency of 0.06. Genetic variants in CDA gene and their frequencies established in our study hold value in pharmacogenetics. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:35 / 39
页数:5
相关论文
共 34 条
[1]  
Abraham A, 2012, PHARMACOGENOMICS, V13, P269, DOI [10.2217/PGS.11.149, 10.2217/pgs.11.149]
[2]  
Amstutz U, 2011, PHARMACOGENOMICS, V12, P1321, DOI [10.2217/PGS.11.72, 10.2217/pgs.11.72]
[3]  
Banklau Chumphorn, 2010, Hematol Oncol Stem Cell Ther, V3, P103
[4]  
Bergman AM, 1998, ADV EXP MED BIOL, V431, P587
[5]  
Boddy AV, 1997, CLIN CANCER RES, V3, P1025
[6]   A Polymorphism in the Cytidine Deaminase Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome [J].
Caronia, Daniela ;
Martin, Miguel ;
Sastre, Javier ;
de la Torre, Julio ;
Angel Garcia-Saenz, Jose ;
Alonso, Maria R. ;
Moreno, Leticia T. ;
Pita, Guillermo ;
Diaz-Rubio, Eduardo ;
Benitez, Javier ;
Gonzalez-Neira, Anna .
CLINICAL CANCER RESEARCH, 2011, 17 (07) :2006-2013
[7]  
Ciccolini J, 2012, PHARMACOGENOMICS, V13, P393, DOI [10.2217/PGS.11.175, 10.2217/pgs.11.175]
[8]   A CDD Polymorphism as Predictor of Capecitabine-Induced Hand-Foot Syndrome-Letter [J].
Ciccolini, Joseph ;
Evrard, Alexandre ;
Lacarelle, Bruno .
CLINICAL CANCER RESEARCH, 2012, 18 (01) :317-317
[9]   Integrating pharmacogenetics into gemcitabine dosing-time for a change? [J].
Ciccolini, Joseph ;
Mercier, Cedric ;
Dahan, Laetitia ;
Andre, Nicolas .
NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (07) :439-444
[10]   Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based Chemotherapies [J].
Ciccolini, Joseph ;
Dahan, Laetitia ;
Andre, Nicolas ;
Evrard, Alexandre ;
Duluc, Muriel ;
Blesius, Aurore ;
Yang, Chenguang ;
Giacometti, Sarah ;
Brunet, Caroline ;
Raynal, Caroline ;
Ortiz, Adrien ;
Frances, Nicolas ;
Iliadis, Athanassios ;
Duffaud, Florence ;
Seitz, Jean-Francois ;
Mercier, Cedric .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :160-165